Annual Information Update

RNS Number : 5115U
Hikma Pharmaceuticals Plc
07 April 2016
 

 

Hikma Pharmaceuticals PLC

Annual Information Update

London, 7 April 2016.  In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the period. In accordance with Prospectus Rule 5.2.7, it is acknowledged that whilst the information referred to in this update was up to date at the time of publication, such disclosures may, at any time, become out of date due to changing circumstances.

 Stock Exchange Announcements

Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/). The Stock Exchange announcements made during the period were:

Date

Headline

07/04/2016

Annual Financial Report

06/04/2016

Blocklisting Interim Review

05/04/2016

Director/PDMR Shareholding

31/03/2016

Director/PDMR Shareholding

29/03/2016

Director/PDMR Shareholding

21/03/2016

Director/PDMR Shareholding

17/03/2016

Director/PDMR Shareholding

16/03/2016

Final Results

03/03/2016

Notice of Results

29/02/2016

Holding(s) in Company

29/02/2016

Holding(s) in Company

29/02/2016

Total Voting Rights

29/02/2016

Roxane Acquisition Close

22/02/2016

Directorate Change

19/02/2016

EGM Statement

11/02/2016

Holding(s) in Company

11/02/2016

Circ re. Roxane Acquisition

10/02/2016

Circ re. Roxane Acquisition

22/01/2016

Circ re. Roxane Acquisition and EGM

07/01/2016

Total Voting Rights

24/12/2015

Shareholders' Agreement and Board Appointment

17/12/2015

Total Voting Rights

03/12/2015

Director/PDMR Shareholding

25/11/2015

Hikma announces sale of Ben Venue manufacturing

24/11/2015

Holding(s) in Company

18/11/2015

Resolution to FDA Warning Letter

16/11/2015

Holding(s) in Company

11/11/2015

Holding(s) in Company

10/11/2015

Holding(s) in Company

02/11/2015

Trading Statement

22/10/2015

Block Listing of Share

19/10/2015

Holding(s) in Company

12/10/2015

Blocklisting Interim Review

08/10/2015

Total Voting Rights

18/09/2015

Audit Tender

16/09/2015

Total Voting Rights

11/09/2015

Director/PDMR Shareholding

27/08/2015

Director/PDMR Shareholding

27/08/2015

Director/PDMR Shareholding

19/08/2015

Director/PDMR Shareholding

19/08/2015

Interim Results

28/07/2015

Acquisition

14/07/2015

Total Voting Rights

18/05/2015

Director/PDMR Shareholding

15/05/2015

Director/PDMR Shareholding

14/05/2015

Result of AGM

14/05/2015

AGM Trading Update

15/04/2015

Holding(s) in Company

10/04/2015

Total Voting Rights

10/04/2015

Director/PDMR Shareholding

09/04/2015

Annual Information Update

All of the above announcements were also made by the Company via the Nasdaq Dubai stock exchange CANDI system.  These announcements may be viewed and downloaded from the Nasdaq Dubai website (www.candi.nasdaq.com). 

 

Documents filed with the Financial Conduct Authority

The Company has filed the following documents with the Financial Conduct Authority ("FCA") via the National Storage Mechanism over the previous 12 months.  These documents are available at http://www.hemscott.com/nsm.do or at the Company's registered office.

Date

Document

07/04/2016

Annual Report and Accounts 2015

07/04/2016

Notice of 2016 Annual General Meeting

07/04/2016

Proxy form for the 2016 Annual General Meeting

Documents filed with Companies House

The Company submitted filings to the Registrar of Companies in England and Wales as detailed in the table below. 

Date Filed

Form

Description

02/03/2016

AP01

Appointment of John Julius Castellani as a director on 1 March 2016

29/02/2016

SH01

Statement of capital following an allotment of shares on 29 February 2016

29/02/2016

AP01

Appointment of Jochen Gann as a director on 29 February 2016

07/01/2016

SH01

Statement of capital following an allotment of shares on 7 January 2016

17/12/2015

SH01

Statement of capital following an allotment of shares on 16 December 2015

09/10/2015

SH01

Statement of capital following an allotment of shares on 9 October 2015

17/09/2015

SH01

Statement of capital following an allotment of shares on 17 September 2015

11/09/2015

AR01

Annual return made up to 7 September 2015 no member list

09/09/2015

SH01

Statement of capital following an allotment of shares on 19 August 2015

15/07/2015

SH01

Statement of capital following an allotment of shares on 13 July 2015

10/06/2015

AA

Group of companies' accounts made up to 31 December 2014

29/05/2015

RESOLUTIONS

RES09 - Resolution of authority to purchase a number of shares
RES10 - Resolution of allotment of securities
RES10 - Resolution of allotment of securities

07/04/2015

SH01

Statement of capital following an allotment of shares on 31 March 2015

 

Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House "Webcheck" at www.companieshouse.gov.uk.

Documents provided to Shareholders

Further Information

Copies of all documents can be obtained from the Company at the registered office which is located at 13 Hanover Square, London W1S 1HW.

 

Peter Speirs

Company Secretary
7 April 2016

 

- ENDS -

 

 

Enquiries:

 

Hikma Pharmaceuticals PLC

 

Peter Speirs

Company Secretary

 

+44 20 7399 2670

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBDLFBQZFZBBB
UK 100

Latest directors dealings